Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06514144 · ClinicalTrials.gov registry record
Exacerbations Among Patients Receiving Breztri (EROS Study)
A clinical trial of Pulmonary Disease and Chronic Obstructive, sponsored by AstraZeneca.
- Completed
- Registry status
- 2,409
- Enrollment target
- 1
- Study location
NCT06514144: Completed study of Pulmonary Disease and Chronic Obstructive, sponsored by AstraZeneca.
NCT06514144 is a study of Pulmonary Disease and Chronic Obstructive that has completed, run by AstraZeneca. The registered enrollment target is 2,409 participants, above the 498-participant average among 19 other Pulmonary Disease trials with a reported enrollment target (384% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06514144, a study of Pulmonary Disease and Chronic Obstructive, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- 2,409 participants
- Enrollment target
- 1
- Study location
Study Summary
EROS was a retrospective analysis of people with COPD using the MORE2 Registry®. Inclusion required ≥1 severe, ≥2 moderate, or ≥1 moderate exacerbation while on other maintenance treatment. Primary outcomes were the rate of COPD exacerbations and healthcare costs for those that received BGF promptly. The effect of each 30-day delay in initiation of BGF was estimated using a multivariable negative binomial regression model.
Primary Outcome
Annualized rates of COPD exacerbation events observed from index date (qualifying exacerbation event) through study completion (until end of data availability), an average follow-up time of 331 days.
Conditions Studied
Interventions
- DRUG BGF
Study Locations (1)
Delaware
- AstraZeneca - Wilmington
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,409 participants |
| Start Date | 2022-10-01 |
| Est. Completion | 2023-03-07 |
What the finished NCT06514144 record still lists
NCT06514144 is an observational study that tracks outcomes without assigning an intervention. Its 2,409 participants enrollment target places it among the larger protocols in the corpus, above the 498-participant average among 19 other Pulmonary Disease trials with a reported enrollment target (384% higher).
The record links to 3 conditions, with Pulmonary Disease appearing as the primary indexed condition, and to 1 intervention - of which BGF is the first listed.
NCT06514144 reports a single indexed study location in Delaware.
Frequently Asked Questions
What is clinical trial NCT06514144 about?
NCT06514144 is a clinical study titled "Exacerbations Among Patients Receiving Breztri (EROS Study)". EROS was a retrospective analysis of people with COPD using the MORE2 Registry®. Inclusion required ≥1 severe, ≥2 moderate, or ≥1 moderate exacerbation while on other maintenance treatment. Primary outcomes were the rate of COPD exacerbations and healthcare costs for those that received BGF promptly...
What is the current status of trial NCT06514144?
This trial is currently completed. The enrollment target is 2,409 participants. The study started on 2022-10-01. Estimated completion is 2023-03-07.
What conditions does trial NCT06514144 study?
This clinical trial studies the following conditions: Pulmonary Disease, Chronic Obstructive, Retrospective Studies.
What interventions are being tested in trial NCT06514144?
The interventions under investigation include: BGF (DRUG).
Who is sponsoring clinical trial NCT06514144?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06514144 being conducted?
This trial has 1 study location across Delaware. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pulmonary Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06514144's enrollment target sits among peer trials
2,409 2nd of 19 the highest of 19 other Pulmonary Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Pulmonary Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Exhaled Breath: A Novel Technique for Rapid Diagnosis of Respiratory Diseases and Infections
RECRUITING
-
Quantitative Pulmonary Imaging Registry & Biorepository
RECRUITING
-
Merck IIT: RRP Pembro and Lenvatinib
RECRUITING · Early Phase 1
-
Study of Lung Proteins in Patients With Pneumonia
RECRUITING
-
Natural History Study of Biomarkers in Pulmonary Arterial Hypertension
RECRUITING
-
Risk Underlying Rural Areas Longitudinal Cohort Study (RURAL) Heart and Lung Study
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05185440 · 2,400 participants · NA
Reducing Alcohol Involved Sexual Violence in Higher Education
- NCT05285527 · 2,400 participants · NA
MiSight 1 Day Safety Post-Approval Study
- NCT05738330 · 2,400 participants · NA
Symptom Monitoring in Hemodialysis
- NCT05833360 · 2,400 participants
Prospective Study of oncRNA Stratification of Cancer by Size and Stage
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI